Business
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus -
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus\n\n\n- VISTAS PSC interim analysis exceeds efficacy threshold for study continuation\n\n\n- Mirum to host conference call to discuss analyses, today, June 17 at 8:30 a.m. ET/5:30 a.m. PT\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced interim results from two Phase 2b studies evaluating volixibat, an oral ileal bile acid transporter (IBAT) inhibitor in patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).\n\n\nInterim results from the VANTAGE study evaluating volixibat in patients with PBC demonstrated a statistically significant (-3.82, p","length":1192,"tagName":"div"}]